000277081 001__ 277081
000277081 005__ 20240229155009.0
000277081 0247_ $$2doi$$a10.1007/s11764-021-01160-1
000277081 0247_ $$2pmid$$apmid:35088246
000277081 0247_ $$2ISSN$$a1932-2259
000277081 0247_ $$2ISSN$$a1932-2267
000277081 0247_ $$2altmetric$$aaltmetric:121751329
000277081 037__ $$aDKFZ-2023-01265
000277081 041__ $$aEnglish
000277081 082__ $$a610
000277081 1001_ $$00000-0003-1976-5831$$avan Leeuwen, Marieke$$b0
000277081 245__ $$aPhase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.
000277081 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2023
000277081 3367_ $$2DRIVER$$aarticle
000277081 3367_ $$2DataCite$$aOutput Types/Journal article
000277081 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687527811_13683
000277081 3367_ $$2BibTeX$$aARTICLE
000277081 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277081 3367_ $$00$$2EndNote$$aJournal Article
000277081 520__ $$aThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors.
000277081 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277081 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277081 650_7 $$2Other$$aCancer survivor
000277081 650_7 $$2Other$$aDisease-free
000277081 650_7 $$2Other$$aHealth-related quality of life
000277081 650_7 $$2Other$$aOncology
000277081 650_7 $$2Other$$aPatient reported outcomes
000277081 650_7 $$2Other$$aSurvivorship questionnaire
000277081 650_2 $$2MeSH$$aHumans
000277081 650_2 $$2MeSH$$aMale
000277081 650_2 $$2MeSH$$aMiddle Aged
000277081 650_2 $$2MeSH$$aQuality of Life
000277081 650_2 $$2MeSH$$aCancer Survivors
000277081 650_2 $$2MeSH$$aNeoplasms: therapy
000277081 650_2 $$2MeSH$$aNeoplasms: diagnosis
000277081 650_2 $$2MeSH$$aSurvivorship
000277081 650_2 $$2MeSH$$aSurveys and Questionnaires
000277081 7001_ $$aKieffer, Jacobien M$$b1
000277081 7001_ $$aYoung, Teresa E$$b2
000277081 7001_ $$aAnnunziata, Maria Antonietta$$b3
000277081 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b4$$udkfz
000277081 7001_ $$aArraras, Juan Ignacio$$b5
000277081 7001_ $$aAutran, Didier$$b6
000277081 7001_ $$aHani, Hira Bani$$b7
000277081 7001_ $$aChakrabarti, Manas$$b8
000277081 7001_ $$aChinot, Olivier$$b9
000277081 7001_ $$aCho, Juhee$$b10
000277081 7001_ $$ada Costa Vieira, Rene Aloisio$$b11
000277081 7001_ $$aDarlington, Anne-Sophie$$b12
000277081 7001_ $$aDebruyne, Philip R$$b13
000277081 7001_ $$aDirven, Linda$$b14
000277081 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b15$$udkfz
000277081 7001_ $$aEller, Yannick$$b16
000277081 7001_ $$aEichler, Martin$$b17
000277081 7001_ $$aFridriksdottir, Nanna$$b18
000277081 7001_ $$aGioulbasanis, Ioannis$$b19
000277081 7001_ $$aHammerlid, Eva$$b20
000277081 7001_ $$avan Hemelrijck, Mieke$$b21
000277081 7001_ $$0P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aHermann, Silke$$b22$$udkfz
000277081 7001_ $$aHusson, Olga$$b23
000277081 7001_ $$aJefford, Michael$$b24
000277081 7001_ $$aJohansen, Christoffer$$b25
000277081 7001_ $$aKjaer, Trille Kristina$$b26
000277081 7001_ $$aKontogianni, Meropi$$b27
000277081 7001_ $$aLagergren, Pernilla$$b28
000277081 7001_ $$aLidington, Emma$$b29
000277081 7001_ $$aLisy, Karolina$$b30
000277081 7001_ $$aMorag, Ofir$$b31
000277081 7001_ $$aNordin, Andy$$b32
000277081 7001_ $$aAl Omari, Amal S H$$b33
000277081 7001_ $$aPace, Andrea$$b34
000277081 7001_ $$aDe Padova, Silvia$$b35
000277081 7001_ $$aPetranovia, Duska$$b36
000277081 7001_ $$aPinto, Monica$$b37
000277081 7001_ $$aRamage, John$$b38
000277081 7001_ $$aRammant, Elke$$b39
000277081 7001_ $$aReijneveld, Jaap$$b40
000277081 7001_ $$aSerpentini, Samantha$$b41
000277081 7001_ $$aSodergren, Sam$$b42
000277081 7001_ $$aVassiliou, Vassilios$$b43
000277081 7001_ $$aLeeuw, Irma Verdonck-de$$b44
000277081 7001_ $$aVistad, Ingvild$$b45
000277081 7001_ $$aYoung, Teresa$$b46
000277081 7001_ $$aAaronson, Neil K$$b47
000277081 7001_ $$avan de Poll-Franse, Lonneke V$$b48
000277081 7001_ $$aQLG, EORTC$$b49$$eCollaboration Author
000277081 773__ $$0PERI:(DE-600)2388888-X$$a10.1007/s11764-021-01160-1$$gVol. 17, no. 4$$n4$$p1111-1130$$tJournal of cancer survivorship$$v17$$x1932-2259$$y2023
000277081 909CO $$ooai:inrepo02.dkfz.de:277081$$pVDB
000277081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000277081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000277081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000277081 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277081 9141_ $$y2023
000277081 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000277081 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000277081 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000277081 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000277081 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER SURVIV : 2022$$d2023-08-25
000277081 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000277081 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000277081 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000277081 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lM110 Epidemiologisches Krebsregister BW$$x2
000277081 980__ $$ajournal
000277081 980__ $$aVDB
000277081 980__ $$aI:(DE-He78)C071-20160331
000277081 980__ $$aI:(DE-He78)C070-20160331
000277081 980__ $$aI:(DE-He78)M110-20160331
000277081 980__ $$aUNRESTRICTED